Autopsy report · NCT00602446

Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant

“Due to slow accrual of patients”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months after it had already started.
• Ran for about 2 years 4 months before it stopped.
• 4 participants enrolled.
• Results were posted on the registry 3 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Masonic Cancer Center, University of Minnesota

Sponsor type

University, hospital or other

Conditions

Breast Cancer; Iron Overload; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes

Interventions

deferasirox

Participants

4

Sites

1

Countries

United States

Trials that died the same way

• Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism
  “Due to slow inclusion of patients” (84% match in meaning)
• Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation
  “Slow accrual and changes in clinical practice” (81% match in meaning)
• Efficacy and Safety Study of Cetuximab or Cetuximab Plus Docetaxel to Treat Prostate Cancer Before Prostatectomy
  “lack of patient population - slow accrual” (80% match in meaning)
• Abiraterone-Rechallenge Study for CRPC Patients
  “Lack of Patient accrual” (77% match in meaning)
• Trial of Two Central Venous Catheter (CVC) Flushing Schemes in Pediatric Hematology and Oncology Patients
  “Poor patient accrual” (76% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.